Feuerstein / Cheifetz Cancer Screening in Inflammatory Bowel Disease

A Guide to Risk Management and Techniques
1. Auflage 2019
ISBN: 978-3-030-15301-4
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 174 Seiten

Reihe: Medicine (R0)

This book provides a concise, yet comprehensive overview of cancer risks in patients with inflammatory bowel disease (IBD), as well as the screening modalities used to reduce these risks. Each chapter presents a major malignancy that patients with IBD are at risk from, stemming from the disease itself or from the medications used to treat the disease. Malignancies covered include colorectal cancer, skin cancer, lymphoma, and other cancers. Cancer risk and screening with current and emerging drug therapies are also discussed. 
Written by experts in the field, Cancer Screening in Inflammatory Bowel Disease: A Guide to Risk Management and Techniques is a valuable resource for gastroenterologists, colorectal surgeons, and primary care physicians who treat and manage patients with inflammatory bowel disease.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Feuerstein, Joseph D.

Cheifetz, Adam S.

Inhaltsverzeichnis

Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases.- Screening for Colon Cancer in Inflammatory Bowel Disease.- Skin Cancer Risk and Screening in Patients with Inflammatory Bowel Disease.- Female Specific Cancern Risks and Screening in Inflammatory Bowel Disease.- Lymphoma Risk and Screening in Inflammatory Bowel Disease.- Pouch Neoplasia following IPAA in Patients with Underlying Inflammatory Bowel Diseases.- Other Cancers: Small Bowel Cancers, Cholangiocarcinoma, Urinary Tract, and Anal Cancer Risk and Screening in Inflammatory Bowel Disease.- Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases.- Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches.- Cancer Risk and Screening in Pediatric Patients.- Colorectal Cancer Risk and Screening in Geriatric Patients.- Use of Biologic Drugs Following an Initial Diagnosis of Malignancy.

Über Autor(innen)

Joseph D. Feuerstein, MDBeth Israel Deaconess Medical CenterCenter for Inflammatory Bowel DiseaseHarvard Medical SchoolBoston, MAUSA
Adam S. Cheifetz, MDBeth Israel Deaconess Medical CenterCenter for Inflammatory Bowel DiseaseHarvard Medical SchoolBoston, MAUSA